is this you? Claim your profile.
is this you? Claim your profile.
Chief of Ophthalmology
HQ Phone:  (303) 436-6000
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
777 Bannock Street MC 0278
Denver Health is the Rocky Mountain Region's Level 1 academic trauma center, and the safety net hospital for the Denver area. The Denver Health system, which integrates acute and emergency care with public and community health, includes the Rocky Mountain Regi... more.
Chief Medical Officer
Associate Professor of Ophthalmology (Part Time)
Flaum Eye Institute at the University of Rochester
Chief Executive Officer
Eyeon Therapeutics, Inc.
Management â€“ ONL Therapeutics
David M. Kleinman, M.D., M.B.A., Chief Medical Officer
Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery and more than ten years experience in venture creation and ophthalmic drug and device development. He currently serves as a part-time associated professor ophthalmology at the Flaum Eye Institute at the University of Rochester, where he specializes in the medical and surgical care of patients with retinal disease. David is the former chief of ophthalmology at Denver Health Medical Center, where he also served as an assistant professor of ophthalmology at the Rocky Mountain Lions Eye Institute. In 2003, he helped found MacuSight, a venture capital backed retinal drug development company, where served as consulting medical director. In his role with MacuSight, David assisted in guiding the company through Series A financing, pre-clinical studies, initial investigational new drug (IND) submission, and Phase I/II clinical development. MacuSight's assets were acquired by Santen in 2010. He holds a bachelor's degree from Brown University, an MBA from the Simon School of Business, and an M.D. with honors from the University of Colorado School of Medicine.
Dr. David M. Kleinman
President, CEO & Co-Founder Eyeon Therapeutics, Inc. Dr. David M. Kleinman is President, CEO, and Co-founder of Eyeon Therapeutics, Inc., an early stage ophthalmology firm developing novel technologies to treat eye diseases. Eyeon Therapeutics and Particle Sciences, Inc. have formed a joint venture to commercialize PEGPLUSTM as an improved therapy for dry eye syndrome. Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery, and he also serves as a part-time Associate Professor of Ophthalmology at the Flaum Eye Institute at the University of Rochester. In addition to running Eyeon Therapeutics and working at the Flaum Eye Institute, he consults for biotechnology, medical device, pharmaceutical, and investment firms nationally. He has helped multiple start-ups develop intellectual property, generate preclinical data, raise money, submit regulatory filings, and complete proof-of-principle and Phase I clinical trials. He also assists larger companies with due diligence and pharmaceutical development in ophthalmology. He is the former Chief of Ophthalmology at Denver Health Medical Center in Denver. He earned his BA from Brown University, his MD with honors from the University of Colorado School of Medicine, and graduated as a Dean's Scholar from the Simon School of Business.
Eyeon Therapeutics Out-Licenses Proprietary OTC Dry Eye Product
David Kleinman, MD, CEO of Eyeon Therapeutics commented, "We are grateful to Particle Sciences for their support in helping us develop and advance this important new technology designed to provide a better treatment opportunity for dry eye patients, and we are delighted to have found an excellent commercial organization to bring this technology to patients with dry eye disease in North America.
David Kleinman, Associate Professor of Ophthalmology - Flaum Eye Institute
David M. Kleinman, MD, MBA, Rocherster, N.Y., and David N. Zacks, MD, PhD, Ann Arbor, Mich.
Dr. Kleinman is a part-time associate professor of ophthalmology at the Flaum Eye Institute at the University of Rochester where he specializes in the medical and surgical care of patients with retinal disease. He has spent more than 10 years working in retinal pharmaceutical development and currently serves as the chief medical officer at ONL Therapeutics Inc.